JournalofSurgicalOncology
AdjuvantImatinibTreatmentafterR0ResectionforPatientsWithHigh-Risk
GastrointestinalStromalTumors:AMedianFollow-Upof44Months
WEI-ZHONGJIANG,MD,1GUO-XIANGUAN,MD,1HUI-SHANLU,MD,1YING-HONGYANG,
DE-YONGKANG,MD,2ANDHE-GUANGHUANG,MD,PhD1*
1
MD,
2
DepartmentofGeneralSurgery,Af liatedUnionHospital,FujianMedicalUniversity,Fuzhou,People’sRepublicofChina2
DepartmentofPathology,Af liatedUnionHospital,FujianMedicalUniversity,Fuzhou,People’sRepublicofChina
Background:TheoptimaldurationofImatinibadjuvanttreatmentforpatientswithhigh-riskgastrointestinalstromaltumors(GISTs)isuncertain.
PatientsandMethods:Atotalof90patientswithhigh-riskGISTsaftercurativeresectionwererecruitedintothisnon-randomizedcase–controlstudy,including35havingImatinibadjuvanttherapyand55havingfollow-upalone.Therecurrence-freesurvival(RFS)wascompared.
Results:Afteramedianfollow-upof44.0months,asigni cantlyreducedrecurrenceratewasobservedinthetreatmentgroupthanthecontrolgroup(17.1%vs.78.2%,P¼0.000).One-year,2-year,and3-yearRFSrateswere100%vs.70.9%,88.0%vs.37.8%,and88.0%vs.27.5%,respectively;withasigni cantadvantageforImatinibadjuvanttherapyversusthesurgeryonly(P¼0.000,HR0.122,95%CI0.041–0.363).ContinuationImatinibtreatmentfurtherimprovedRFSbycomparisonwiththeinterruptiontreatment(both2-yearand3-yearRFSwere95.8%vs.63.6%,P¼0.011,HR0.103,95%CI0.012–0.883).Therewerenoseriousadverseeventsintheadjuvanttherapygroup.
Conclusions:ImatinibAdjuvanttherapycouldsigni cantlyprolongtheRFSofpatientswithhigh-riskGISTs.ExtendedImatinibadjuvanttreatmentstrategymayfurtherreducetheriskofrelapsewithalowdrugresistancerateandtoxicitypro le.
J.Surg.Oncol.ß2011Wiley-Liss,Inc.
KEYWORDS:GISTs;Imatinib;adjuvanttherapy;recurrence-freesurvival;adverseevents
INTRODUCTION
Incurrentclinicalpractice,completesurgicalresection(R0)remainsthemaintreatmentapproachforgastrointestinalstromaltumors(GISTs).Unfortunately,over85%ofhigh-riskGISTspatientshavelocaltumorrelapseand/ormetastasesevenafteranR0resec-tion,witha5-yearrecurrence-freesurvivalofonly20–40%reported[1–4].Thesetumorsarealsoratherresistanttoradiotherapyandtoconventionalchemotherapy.Thus,developingatreatmentstrategytoreducetumorrecurrenceandprolongoverallsurvival(OS)isveryimportantforthepatientswithhigh-riskdisease.
RecentstudiessuggestthatGISTsarisefromtheinterstitialcellsofCajal.TheyarecharacterizedbyanoverexpressionoftheKITreceptorprotein(CD117)inapproximately80%ofpatients,andCD117hasbecomeapotentialtargetfortherapy[5–7].Imatinibmesylateisaspeci csmall-moleculetyrosinekinaseinhibitorinitiallydevelopedfortreatingChronicMyeloidLeukemia(CML).Ithasbeenshowntohaveclinicalbene tinover80%ofpatientswithmetastaticGISTs,withlowtoxicitypro lereportedinmulticenterclinicaltrialsintheUSandFinland(STIB2222),Europe(EORTCSoftTissueandSarcomaGroup),andAustralia(AustralianGastroIntestinalTrialsGroup).TheB2222trailshowedthat75%ofpatientswithunresectableormetastaticGISTstreatedwithImatinibhadapartialresponseorstablediseasewithamedianOSofapprox-imately57months[8,9].Thesedatahaveledtoquestionsontheadjuvantuseofthisagentforhigh-riskpatientstopreventrecurrenceofafterR0resection.
In2007,Nilssonetal.[10]reportedanobviousRFSadvantageofImatinibadjuvanttherapyforpatientswithGISTswithahigh
malignantpotential.Multiplecurrentprospectiverandomizedtrials(ACOSOGZ9000,ACOSOGZ9001,EORTC,andSSGXVIII)alsohaveaddressedtheroleofImatinibadjuvanttherapyindifferentgroupsofpatients.However,theoptimaldurationofadjuvanttreat-mentisuncertain.Thisstudywastoevaluatetheef cacyandsafetyofextendingImatinibadjuvanttherapyfor5yearsinhigh-riskGISTspatientsafterR0resection.Resultsatamedianfollow-upof44monthswerereportedhere.
PATIENTSANDMETHODS
Patients
FromApril2002toSeptember2009,weprospectivelygatheredclinicaldataon90consecutivepatientswithCD117positivehigh-riskGISTswhohadanR0resectionattheDepartmentofGeneralSurgery,theAf liatedUnionHospitalofFujianMedicalUniversity.Detailedinformationonpatientdemographics,tumorsites,operationperformed,andhistopathologicstudieswereallavailable.The
JiangWZandGuanGXcontributedequallytothiswork.
*Correspondenceto:He-GuangHuang,MD,PhD,DepartmentofGeneralSurgery,Af liatedUnionHospitalofFujianMedicalUniversity,29XinquanRoad,Fuzhou,350001,FujianProvince,People’sRepublicofChina.Fax:86-591-87113828.E-mail:HHUANG2@yahoo.cnReceived3April2011;Accepted8June2011DOI10.1002/jso.22010
PublishedonlineinWileyOnlineLibrary(wileyonlinelibrary.com).
ß2011Wiley-Liss,Inc.
after curative treatment for patients with vira ...resection, ablation therapy or liver transplantation...rm the ef?cacy of adjuvant interferon therapy ...
imatinib after 1, 3, or 5 years of treatment ...for patients with resected ‘high-risk’ GIST; ...ts. Key words: adjuvant, advanced, ...
risk factor for OS after R0 resection. ...these patients for adjuvant TACE treatment are ...Consistent with these results, ICC with high GGT...
Adjuvant treatment in biliary tract cancer to ...On the other hand, patients with high risk ...patients with macroscopically positive resection ...
Adjuvant Imatinib Trea... 5页 免费 Discordantly high spin... 暂无评价 7...treatment patients with metastases=>early initiation of androgen withdrawal and...
Adjuvant Neoadjuvant Time of rectal resection ...Definition and treatment of anastomotic leakage The...(1990) Adjuvant therapy for patients with colon ...
adjuvant chemotherapy with S-1 for Korean ...treatment prior to the planned eight cycles were ...with resection of regional lymph nodes is the ...
adjuvant chemotherapy to patients with high-risk ...after resection of the primary tumour, as in ...Treatment with sipuleucel-T in this earlier ...
Adjuvant treatment after salvage surgery Primary ...For patients with unfavourable pathological features,... a) intermediate-risk: clear resection margins ...
the optimal adjuvant treatment strategy – Asia: Radical resection (D2) ? ...3 years adjuvant imatinib is better than 1 year in high risk patients –...
热门文档